Travere Therapeutics receives FDA accelerated approval for FILSPARI
Travere Therapeutics has received the US Food and Drug Administration (FDA) accelerated approval for FILSPARI (sparsentan).
Stay updated with breaking news from Deric Dube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Travere Therapeutics has received the US Food and Drug Administration (FDA) accelerated approval for FILSPARI (sparsentan).
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from...
18.02.2023 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI (sparsentan) to reduce ... Seite 1
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartanLi...
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from...